Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas

Table 1 Clinical characteristics of 43 patients with gastric neuroendocrine carcinomas

Clinicopathological feature	n (%)
Age (yr)
< 60/≥ 60	15 (34.88)/28 (65.12)
mean ± SD	62.26 ± 10.46
Gender
Male/female	35 (81.40)/8 (18.60)
Tumor location
Cardia	21 (48.84)
Corpus	10 (23.26)
Antrum	10 (23.26)
Residual stomach anastomosis	2 (4.65)
Tumor size (max diameter, cm)
≤ 5/> 5	20 (46.51)/23 (53.49)
mean ± SD	5.47 ± 3.18
T classification
T1/T2/T3/T4	0 (0)/4 (9.30)/0 (0)/39 (90.70)
Lymph node metastasis
N0/N1	12 (27.91)/31 (72.09)
Liver metastasis
Absent/present	37 (86.05)/6 (13.95)
Pathological stage
I/II/III/IV	0 (0)/2 (4.65)/35 (81.40)/6 (13.95)
Pathology
Small cell carcinomas	39 (90.70)
Large cell carcinomas	4 (9.30)
Operation
Curative resection	38 (88.37)
Palliative resection	5 (11.63)
Neoadjuvant therapy
No/present	100 (100)/0 (0)
Follow-up
Median OS (mo)	31.0

Patients were staged in accordance with the 7th Edition of the AJCC Cancer TNM Classification. OS: Overall survival.